# NAD Augmentation in Diabetes Kidney Disease

Study · id `cardio:ct-nct05759468` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05759468](<https://clinicaltrials.gov/study/NCT05759468>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05759468

Browse, organ or system: Kidneys; Metabolism  
Browse, condition area: Diabetes and metabolic disease; Kidney connections  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 156 participants.

## Technical summary

Registry record NCT05759468. Randomized; quadruple masking; primary purpose treatment. Start 2023-04-13 (actual); primary completion 2026-11-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 156 participants (planned count; ClinicalTrials.gov record NCT05759468, source copy `cardio:ctgov-nct05759468-2026-04-13`, retrieved 2026-10-26)
- Started: 2023-04-13 (actual) (ClinicalTrials.gov record NCT05759468, source copy `cardio:ctgov-nct05759468-2026-04-13`, retrieved 2026-10-26)
- Primary completion: 2026-11-30 (anticipated) (ClinicalTrials.gov record NCT05759468, source copy `cardio:ctgov-nct05759468-2026-04-13`, retrieved 2026-10-26)
- Completion: 2027-03-31 (anticipated) (ClinicalTrials.gov record NCT05759468, source copy `cardio:ctgov-nct05759468-2026-04-13`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT05759468, source copy `cardio:ctgov-nct05759468-2026-04-13`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05759468-2026-04-13`, retrieved 2026-10-26)

## The registry's words

- Brief title: NAD Augmentation in Diabetes Kidney Disease
- Acronym: DKD
- Condition: Type2diabetes
- Condition: Diabetic Kidney Disease
- Intervention (Drug): Investigational Product - MIB 626
- Intervention (Drug): Placebo
- Lead sponsor: Brigham and Women's Hospital
- Lead sponsor class: OTHER
- Collaborator: Boston Medical Center
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Diabetic kidney disease (`cardio:diabetic-nephropathy`)
- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: Brigham and Women's Hospital (`cardio:org-brigham-and-women-s-hospital`)
- Registry lists this organization as a collaborator: Boston Medical Center (`cardio:org-boston-medical-center`)

## Provenance

Content hash: 876b8d243adcd7efadc9f0ae4dd0645b2a29701900bf7ed458d647e7f2a174c7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
